Trial results

$DNTH — claseprubart

Dianthus Therapeutics, Inc. /DE/ (DNTH) claseprubart: trial results in Multifocal Motor Neuropathy (MMN), 2026.

Research by Catalyst Intel

The catalyst

"In August 2026, we announced the completion of enrollment of the MoMeNtum trial, which exceeded its enrollment target of 36 patients, and top-line results with 46 patients are expected in December 2026."

— Dianthus Therapeutics, Inc., 10-Q filed 2026-11-04 · the filing. Checked word for word against the stored document when this page was built; a sentence that did not check out would not be here.

Event id

DNTH-CLASEPRUBART-2026

Company

Dianthus Therapeutics, Inc. /DE/

Kind

Trial results

Indication

Multifocal Motor Neuropathy (MMN)

Window

2026-12-01 – 2026-12-31

Status

dropped

The bar

No bar has been published for this event yet.

Verdicts

No verdict has been published for this event yet.